Article and Video CATEGORIES
Actually, it's some background information and your blood that's needed.
Memorial Sloan-Kettering is running an important trial that is trying to determine some of the molecular factors that lead some never-smokers to develop lung cancer while other never-smokers don't. The trial is just a one-time collection of information in a questionnaire, I believe about medical history and environmental exposures, and submission of two vials of blood. There is no cost to participants, with all packaging and mail expenses pre-paid, and the registration and additional information is online here.
This is an important and timely question, and the researchers at Memorial Sloan-Kettering have been among the most important leaders in developing our understanding of the biology of not only never-smoker lung cancer, but also of lung cancer in general. I strongly encourage any never-smoker with lung cancer to participate.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…